Target intelligence / Profile preview

Influenza A/H3N2 hemagglutinin antigen (HA)

Target
HA
Molecular classification
Receptor, Other
01

Overview

Influenza A/H3N2 hemagglutinin antigen (HA) is a major surface glycoprotein of the influenza A virus subtype H3N2, playing a critical role in the initiation of viral infection. It functions as a class I viral fusion protein, consisting of two subunits, HA1 and HA2, which form a homotrimer on the viral envelope. The HA1 subunit mediates the attachment of the virus to host cell surface receptors containing alpha-2,6-linked sialic acid, while the HA2 subunit facilitates the fusion of the viral envelope with the endosomal membrane under low-pH conditions. Because of its essential role in viral entry, HA is the primary target of the host neutralizing antibody response and the immunodominant component of seasonal influenza vaccines. It is also a key target for antiviral drug development, including small-molecule fusion inhibitors like umifenovir (Arbidol) and investigational monoclonal antibodies like diridavumab, which aim to block viral entry or membrane fusion. However, the high rate of antigenic drift and the emergence of egg-adaptive mutations during vaccine production present significant challenges to maintaining vaccine and therapeutic efficacy.

Other names
HemagglutininH3N2 HAH3 hemagglutininInfluenza A virus H3N2 hemagglutininHemagglutinin glycoproteinHA1HA2
02

Mechanism of action

Inhibition of viral entry and membrane fusion by binding to the hemagglutinin protein, preventing the low pH-induced conformational change required for fusion of the viral envelope with the host endosomal membrane.

03

Biological functions

Immune responseOther
04

Disease associations

InfectionOther
05

Safety considerations

Antigenic drift leading to vaccine mismatchEgg-adaptive mutations during vaccine manufacturingEmergence of drug resistanceHypersensitivity reactions
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HAI) titerNeutralizing antibody titerViral load

Beyond the preview

Go deeper on Influenza A/H3N2 hemagglutinin antigen (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A/H3N2 hemagglutinin antigen (HA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call